目前，抗体治疗已成为肿瘤治疗的一线治疗策略。截至2013年，美国FDA已批准了针对EGFR的西妥昔单抗（cetuximab）、针对HER2的曲妥珠单抗（trastuzumab）、针对CD20的利妥昔单抗（rituximab）、针对VEGF的贝伐单抗（bevacizumab）以及针对CTLA-4的伊匹单抗（ipilimumab）等抗体药物用于肿瘤的临床治疗。同时，随着新型抗体不断研发，例如针对PD-1分子的MDX-1106和BMS-936558均已进入临床试验阶段，使得抗体治疗成为目前肿瘤治疗的研究热点，也是转化医学最成功的范例之一。本文以FDA批准的针对HER2、CD20、VEGF以及CTLA-4的抗体，并结合目前处于临床试验阶段的抗体为例，介绍用于肿瘤治疗的治疗性抗体在临床转化中的研究进展。

Antibody therapy has become the first-line treatment strategy for cancer patients. As of 2013, several antibodies including Cetuximab, Trastuzumab, Rituximab, Bevacizumab, and Ipilimumab have been approved by the Food and Drug Administration (FDA) of the United States for use in clinics to treat cancer patients. It is believed that use of cancer therapeutic antibodies in clinics is the most successful example of translational medicine. Moreover, development of novel cancer therapeutic antibodies has become the spotlight of research in recent years, and several potential antibodies, like MDX-1106 and BMS-936558 targeting PD-1, have entered into clinical trials. In this paper, we aim to review the performance the FDA-approved therapeutic antibodies targeting EGFR, HER2, CD20, VEGF, and CTLA-4 in clinical settings and the progress on the novel therapeutic antibodies under clinical trials.

国家重点基础研究发展计划(973计划)资助项目（No.2013CB530500）；国家自然科学基金项目(No.81172146)